Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Paper
  • Published:

Mammalian Chk2 is a downstream effector of the ATM-dependent DNA damage checkpoint pathway

Abstract

In response to DNA damage and replication blocks, cells activate pathways that arrest the cell cycle and induce the transcription of genes that facilitate repair. In mammals, ATM (ataxia telangiectasia mutated) kinase together with other checkpoint kinases are important components in this response. We have cloned the rat and human homologs of Saccharomyces cerevisiae Rad 53 and Schizosaccharomyces pombe Cds1, called checkpoint kinase 2 (chk2). Complementation studies suggest that Chk2 can partially replace the function of the defective checkpoint kinase in the Cds1 deficient yeast strain. Chk2 was phosphorylated and activated in response to DNA damage in an ATM dependent manner. Its activation in response to replication blocks by hydroxyurea (HU) treatment, however, was independent of ATM. Using mass spectrometry, we found that, similar to Chk1, Chk2 can phosphorylate serine 216 in Cdc25C, a site known to be involved in negative regulation of Cdc25C. These results suggest that Chk2 is a downstream effector of the ATM-dependent DNA damage checkpoint pathway. Activation of Chk2 might not only delay mitotic entry, but also increase the capacity of cultured cells to survive after treatment with γ-radiation or with the topoisomerase-I inhibitor topotecan.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6

Similar content being viewed by others

References

  • Allen JB, Zhou Z, Siede W, Friedberg EC and Elledge SJ. . 1994 Genes Dev. 8: 2401–2415.

  • Barlow C, Hirotsune S, Paylor R, Liyanage M, Eckhaus M, Collins F, Shiloh Y, Crowley JN, Ried T, Tagle D and Wynshaw-Boris A. . 1996 Cell 86: 159–171.

  • Biemann K. . 1990 In: McCloskey JA. (ed.). Methods in Enzymology, Vol 193 Academic Press. New York pp. 886–887.

    Google Scholar 

  • Bentley NJ, Holtzman DA, Flaggs G, Keegan KS, DeMaggio A, Ford JC, Hoekstra M and Carr AM. . 1996 EMBO J. 15: 6641–6651.

  • Blasina A, Van de Weyer I, Laus MC, Luyten WHML, Parker AE and McGowan CH. . 1999 Curr. Biol. 9: 1–10.

  • Boddy MN, Furnari B, Mondesert O and Russell P. . 1998 Science 280: 909–912.

  • Carr SA, Huddleston MJ and Annan RS. . 1996 Anal. Biochem. 239: 180–192.

  • Cimprich KA, Shin TB, Keith CT and Schreiber SL. . 1996 Proc. Natl. Acad. Sci. USA 93: 2850–2855.

  • Elledge SJ. . 1996 Science 274: 1664–1672.

  • Hartwell LH and Weinert TA. . 1989 Science 246: 629–634.

  • Hofmann K and Bucher P. . 1995 Trends Biochem Sci. 20: 347–349.

  • Huang M, Zhou Z and Elledge SJ. . 1998 Cell 94: 595–605.

  • Kastan MB, Zhou Q, El-Diery WS, Carrier F, Jacks T, Walsh WV, Plunkett BS, Vogelstein B, Fornace Jr AJ. . 1992 Cell 71: 587–597.

  • Keegan KS, Holtzman DA, Plug AW, Christenson ER, Brainerd EE, Flaggs G, Bentley NJ, Taylor EM, Meyn MS, Moss SB, Carr AM, Ashley T, Hoekstra MF. . 1996 Genes Dev. 10: 2423–2437.

  • Kingsbury WD, Boehm JC, Jakas DR, Holden KG, Hecht SM, Gallagher G, Caranfa MJ, McCabe FL, Faucette LF, Johnson RK and Hertzberg RP. . 1991 J. Med. Chem. 34: 98–107.

  • Lindsay HD, Griffiths DJF, Edwards RJ, Christensen PU, Murray JM, Osman F, Walworth N and Carr AM. . 1998 Genes Dev. 12: 382–395.

  • Matsuoka S, Huang M and Elledge SJ. . 1998 Science 282: 1893–1897.

  • Maundrell K. . 1990 J. Biol. Chem. 265: 10857–10864.

  • Murakami H and Okayama H. . 1995 Nature 374: 817–819.

  • Murray AW. . 1995 Curr. Opin. Genet. Dev. 5: 5–11.

  • Paulovich AG and Hartwell LH. . 1995 Cell 82: 841–847.

  • Painter RB and Young BR. . 1980 Proc. Natl. Acad. Sci. USA 77: 7315–7317.

  • Peng CY, Graves PR, Thoma RS, Wu Z, Shaw AS and Piwnica-Worms H. . 1997 Science 277: 1501–1505.

  • Ryan AJ, Squires S, Strutt HL, Evans A, Johnson RT. . 1994 Carcinogenesis 15: 823–828.

  • Sanchez Y, Desany BA, Jones WJ, Liu Q, Wang B and Elledge SJ. . 1996 Science 271: 357–360.

  • Sanchez Y, Wong C, Thoma RS, Richman R, Wu Z, Piwnica-Worms H and Elledge SJ. . 1997 Science 277: 1497–1501.

  • Santocanale C and Diffley JFX. . 1998 Nature 395: 615–617.

  • Savitsky K, Bar-shira A, Gilad S, Rotman G, Ziv Y, Vanagaite L, Tagle DA, Smith S, Uziel T, Sfez S, Ashkenazi LP, Frydman M, Harnik R, Sankhavaram RP, Simmons A, Clines GA, Sartiel A, Gatti RA, Chessa L, Sanal O, Lavin MF, Jaspers NGJ, Taylor MR, Arlett CF, Miki T, Weissman SM, Lovett M, Collins F and Shiloh Y. . 1995 Nature 268: 1749–1753.

  • Scudiero DA, Shoemaker RH, Pauli KD, Monks A, Tierney S, Nofziger TH, Currens MJ, Seniff D and Boyd MR. . 1988 Cancer Res. 48: 4827–4834.

  • Shirahige K, Hori Y, Shiraishi K, Yamashita M, Takahashi K, Obuse C, Tsurimoto T and Yoshikawa H. . 1998 Nature 395: 618–621.

  • Sun Z, Fay DS, Marini F, Foiani M and Stern DF. . 1996 Genes Dev. 10: 395–406.

  • Sun Z, Hsiao J, Fay DS and Stern DF. . 1998 Science 281: 272–274.

  • Walworth N, Davey S and Beach D. . 1993 Nature 363: 368–371.

  • Walworth N and Bernard R. . 1996 Science 271: 353–356.

  • Weichselbaum RR, Nove J and Little JB. . 1978 Nature 271: 261–262.

  • Weinert TA, Kiser GL and Hartwell LH. . 1994 Genes Dev. 8: 652–665.

  • Zeng Y, Forbes KC, Wu Z, Moreno S, Piwnica-Worms H and Enoch T. . 1998 Nature 395: 507–510.

  • Zhang X, Herring CJ, Romano PR, Szczepanowska J, Breska H, Hinnebusch and Qin J. . 1998 Anal Chem. 70: 2050–2059.

  • Ziv Y, Bar-Shira A, Pecker I, Russell P Jorgensen TJ, Tsarfate I and Shiloh Y. . 1997 Oncogene 15: 159–167.

Download references

Acknowledgements

We thank Jeff Jackson and Amy Roshak for discussion and suggestions during the course of this work, John D Martin for peptide synthesis, Mike Hansbury for technical help, Jackson Wong and Doug Fecteau for assistance in tissue culture work. We thank Kristi Forbes, Hiroto Okayama and Paul Russell for providing S. pombe Cds1 constructs ΔCds1 strains. P Chaturvedi is a postdoctoral fellow supported by National Cancer Institute grant (CA-50771-09).

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Bin-Bing S Zhou.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Chaturvedi, P., Eng, W., Zhu, Y. et al. Mammalian Chk2 is a downstream effector of the ATM-dependent DNA damage checkpoint pathway. Oncogene 18, 4047–4054 (1999). https://doi.org/10.1038/sj.onc.1202925

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1202925

Keywords

This article is cited by

Search

Quick links